Registration, quality assurance and the shape of a medicines contract
A medicines tender is decided on quality assurance before it is decided on price. Bidders must show that the product is authorised or registered for use in the destination market, that it is manufactured at a site holding current good manufacturing practice certification, and -- for many donor-funded and essential medicines programs -- that the product or its manufacturer appears on a recognised prequalification list. These are documentary conditions of admissibility assessed against the specific product and manufacturing site offered, and a change of site after award is a contractual event, not an administrative one.
Products are specified by international non-proprietary name, strength and dosage form so that generics compete openly, with pharmacopoeial standards cited for quality. Delivery conditions carry as much weight as the product: a minimum proportion of shelf life remaining on arrival, batch certificates of analysis, tamper-evident and correctly labelled packaging in the required language, and unbroken cold chain with temperature monitoring for products that need it. A consignment that arrives with too little shelf life left is routinely rejected at the buyer's cost to the supplier.
The commercial structure is usually a framework at agreed unit prices with call-offs against forecast rather than firm volume, because demand depends on disease patterns and program funding. That places emphasis on lead times, on the supplier's obligation to hold or replenish stock, and on what happens in a shortage -- allocation, substitution and notification terms are increasingly explicit. Recall capability is tested rather than assumed: buyers ask how quickly a batch can be traced and withdrawn from every facility it reached.
This section describes how this category is bought generally, across the public buyers that publish it. The figures elsewhere on this page are measured for this market alone.
Who buys pharmaceuticals in Netherlands?
GlobalGov holds 579 pharmaceuticals records from 188 distinct buying organizations in Netherlands. The most frequent publishers are Gemeente Den Haag (20 records); Gemeente Rotterdam (19 records); Ministerie van Defensie (18 records); Gemeente Leeuwarden (14 records); Gemeente Maastricht (12 records); Gemeente Eindhoven (9 records). Between them the 6 largest account for 16% of everything published, so buying here is spread across many separate authorities.
| Buying organization | Records | Share |
|---|---|---|
| Gemeente Den Haag | 20 | 3.5% |
| Gemeente Rotterdam | 19 | 3.3% |
| Ministerie van Defensie | 18 | 3.1% |
| Gemeente Leeuwarden | 14 | 2.4% |
| Gemeente Maastricht | 12 | 2.1% |
| Gemeente Eindhoven | 9 | 1.6% |
What are pharmaceuticals contracts worth in Netherlands?
184 of the 579 records publish a contract value. The median is $2.2M and the largest single published value is $1.7B. By size, 24 under $100k, 33 between $100k and $1M, 92 between $1M and $10M, 35 above $10M. The remaining 395 publish no value at all, so every figure here describes the priced subset only, and values are as stated by the buyer rather than as finally awarded.
| Contract size | Records | Share of priced |
|---|---|---|
| under $100k | 24 | 13% |
| between $100k and $1M | 33 | 18% |
| between $1M and $10M | 92 | 50% |
| above $10M | 35 | 19% |
How long do bidders get to respond to pharmaceuticals tenders in Netherlands?
Across the 125 Netherlands pharmaceuticals notices that publish both a publication date and a closing date, the median response window is 50 days. A quarter of them allowed 42 days or fewer and a quarter stayed open for more than 62. Not one of them closed within a fortnight of being published, so the window on this market is consistently workable.
How often are pharmaceuticals tenders published in Netherlands?
Netherlands publishes about 13 notices a month in this category, 161 in the last twelve months. That is 127% more than the 71 published in the twelve months before that. Over the last three years there were 312, spread across 65 separate months of activity since 21 September 2016. May is historically the busiest month. No new notice has been published in this category since 26 May 2026, 180 days ago, so treat the figures above as a record of the market rather than as this week's pipeline.
How does Netherlands compare with other pharmaceuticals markets?
Among the 45 countries where GlobalGov holds a comparable pharmaceuticals market, Netherlands ranks 17th by number of records. The largest is Poland (9,417 records against 579 here). Within Netherlands itself, pharmaceuticals is the 23rd largest of the 67 procurement categories tracked here.
Where do the Netherlands pharmaceuticals records on this page come from?
These 579 records are collected from 1 official source: TED (579). GlobalGov is an independent aggregator and is not affiliated with any of them; each record links back to the notice on its issuing portal. The set is rebuilt nightly, and the counts on this page were taken on 2026-11-22.
Most recent Pharmaceuticals tenders in Netherlands
No individual notice in this category currently has a public record page. The market figures above are computed over all 579 records GlobalGov holds for it.
Other procurement categories in Netherlands
Pharmaceuticals procurement in other markets
Never Miss a Netherlands Government Contract
Finding Netherlands tenders usually means a local portal, a local registration and someone who reads the language. Get an alert you can read when a new pharmaceuticals opportunity is published there.
Start Free Trial